WALTHAM, Mass.--(BUSINESS WIRE)--BG Medicine announced today that Laboratory Corporation of America® Holdings (LabCorp®)now offers galectin-3 testing services using the BGM Galectin-3 test for heart failure. The BGM Galectin-3 test was cleared by the FDA in November 2010 as an aid in assessing the prognosis of patients with chronic heart failure. Elevated galectin-3 levels are associated with an inherently progressive form of heart failure that is associated with an increased risk of hospitalization or death. LabCorp provides convenient access to galectin-3 testing for physicians and their patients throughout the United States.
